Eli Lilly’s insulin candidate efsitora alfa has achieved its main goals in a further two trials, which belong to the QWINT phase 3 development program. These two trials, QWINT-2 and QWINT-5, mainly looked at the change in A1C, an indicator of the patient’s glycaemic control. The data was published in The New England Journal of […] The post Eli Lilly Sees Second Round of Positive Data on Weekly Insulin Candidate appeared first on LifeSci Voice ..read more

Viridian announced that veligrotug, its potential thyroid eye disease (TED) drug, recorded impressive results in managing TED during a late-phase trial. The increase in effectiveness puts the drug in a lineup to become a rival to Amgen’s Tepezza. The trial demonstrated that the company met both the primary and the secondary endpoints in the management […] The post Viridian Drug Successfully Meets Study Objectives as Treatment for Thyroid Eye Disease appeared first on LifeSci Voice ..read more

Terns Pharmaceuticals’ decision to move away from the liver disease field may turn out to be beneficial since early phase 1 data suggests that another of its candidates – TERN-601 – may also be effective in reducing weight. To assess the acute pharmacodynamics effect of TERN-601 in healthy overweight/obese adult volunteers a randomized, double-blind, placebo-controlled […] The post Tern’s oral GLP-1 achieves 5% weight reduction within one month at the highest dose appeared first on LifeSci Voice ..read more

Genesis Therapeutics’ AI drug discovery platform, GEMS, has gained popularity and now attracted the attention of Gilead Sciences with a $35M partnership. In a major deal, Gilead will pay $35 million to Genesis as part of a new partnership for AI-based drug discovery focused on three undisclosed targets. Additionally, Gilead “will have the option to […] The post Gilead and AI Drug Discovery Company Genesis Sign $35 Million Partnership appeared first on LifeSci Voice ..read more

Brightflow SAS, a privately owned company at the forefront in the area of long-term percutaneous mechanical circulatory assistance for the treatment of patients in the latter stages of heart failure, has managed to raise $18 million in equity Series A investment. Brightflow’s goal is to provide a completely noninvasive long-term circulatory support system for the […] The post Brightflow SAS Nabs $18M For Heart Failure Solution appeared first on LifeSci Voice ..read more

Relay Therapeutics released interim Phase I/II data showing that RLY-2608, its investigational PI3Kα inhibitor, demonstrated “clinically meaningful” progression-free survival (PFS) in patients with specific molecular subtypes of metastatic breast cancer. The study, called ReDiscover, enrolled patients with locally advanced or metastatic breast cancer that was PI3Kα-mutated, ER-positive, and HER2-negative. RLY-2608 was administered at its recommended […] The post Relay Wins Early on Breast Cancer, Arranges Crucial Trial Against Truqap from AstraZeneca appeared first on LifeSci Voice ..read more

After successfully completing two trials, SWIFT-1 and SWIFT-2, for its long-acting asthma drug depemokimab, GSK has now shared results for its Phase 3 trial. These trials demonstrated the treatment’s ability to reduce the number of asthma attacks experienced by participants by half, achieving the primary endpoint of the study. Although it was announced in May […] The post GSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial appeared first on LifeSci Voice ..read more

Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of three Phase 3 trials. Tolebrutinib was being evaluated across two forms of chronic neurological disorder. The HERCULES trial included patients with non-relapsing secondary progressive MS, while two identical Phase 3 studies, known as GEMINI 1 and 2, were conducted on patients with […] The post Sanofi’s Tolebrutinib faces defeat in 2 out of 3 phase 3 MS trials appeared first on LifeSci Voice ..read more

In a decision expected to limit Brussels’ merger authority, American gene sequencing firm Illumina prevailed in court against the European Union’s inquiry into its $7.1 billion purchase of cancer diagnostic test manufacturer Grail. Illumina, which created Grail and spun it off in 2016, before re-acquiring it in 2021 for just over $7 billion, went up […] The post Illumina Gets Favorable Decision Regarding Grail Acquisition appeared first on LifeSci Voice ..read more

Onward Medical revealed that it has received a major grant from the Christopher & Dana Reeve Foundation to continue with BCI research. This $1.1M grant will fund increasing an existing early-phase clinical feasibility study; this study is exploring the potential use of Brain-Computer Interfaces (BCI) to enable the use of hands and arms through thought […] The post Onward awarded $1.1M grant from the Christopher & Dana Reeve Foundation to advance BCI research appeared first on LifeSci Voice ..read more